Journey Medical (DERM) Corporation announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi, the Company’s recently launched treatment for the inflammatory lesions of rosacea in adults. This compares to 29% of commercial lives in May 2025. Journey Medical continues to execute on the launch of Emrosi, with expanded payer coverage anticipated to facilitate further growth in total prescription demand.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
- Journey Medical Corp Holds 2025 Annual Stockholders Meeting
- Journey Medical Joins Russell 2000 and 3000 Indices
- Journey Medical to join Russell 2000, Russell 3000 Indexes
- Journey Medical announces data analysis from Phase 3 trials of Emrosi
- Journey Medical announces Emrosi featured on “The Balancing Act”